Numis Securities Ltd reissued their buy rating on shares of Vectura Group PLC (LON:VEC) in a research note released on Thursday. The brokerage currently has a GBX 205 ($2.72) price target on the stock.

A number of other equities analysts have also recently issued reports on VEC. Shore Capital reaffirmed a buy rating on shares of Vectura Group PLC in a research note on Wednesday, August 16th. Peel Hunt reaffirmed a hold rating and issued a GBX 160 ($2.12) price objective on shares of Vectura Group PLC in a research note on Wednesday, August 16th. J P Morgan Chase & Co reduced their price objective on shares of Vectura Group PLC from GBX 210 ($2.79) to GBX 180 ($2.39) and set an overweight rating on the stock in a research note on Thursday, September 21st. Citigroup Inc. reduced their price target on shares of Vectura Group PLC from GBX 200 ($2.65) to GBX 180 ($2.39) and set a buy rating on the stock in a research report on Monday, September 18th. Finally, N+1 Singer reissued a hold rating on shares of Vectura Group PLC in a research report on Thursday, June 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Vectura Group PLC has a consensus rating of Buy and a consensus target price of GBX 199.63 ($2.65).

Shares of Vectura Group PLC (LON VEC) opened at 103.80 on Thursday. The firm’s market capitalization is GBX 704.28 million. The firm’s 50-day moving average is GBX 105.27 and its 200 day moving average is GBX 121.47. Vectura Group PLC has a 52 week low of GBX 88.90 and a 52 week high of GBX 166.97.

WARNING: “Vectura Group PLC (VEC) Earns Buy Rating from Numis Securities Ltd” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/08/vectura-group-plc-vec-earns-buy-rating-from-numis-securities-ltd.html.

In related news, insider Andrew Derodra acquired 82,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were acquired at an average cost of GBX 90 ($1.19) per share, for a total transaction of £73,800 ($97,890.97). Also, insider Bruno Angelici acquired 70,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The shares were bought at an average price of GBX 99 ($1.31) per share, for a total transaction of £69,300 ($91,922.01). Over the last three months, insiders have bought 152,293 shares of company stock worth $14,339,837.

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.